Abstract:Objective To investigate the clinical value of serum metabonomic profile of pancreatic cancer using nuclear magnetic resonance (NMR)-based metabonomics.Methods The retrospective case-control study was adopted.The clinical data of 23 patients with pancreatic cancer (PC group) and 16 healthy volunteers (control group) who were admitted to the Fujian Medical University Union Hospital between December 2013 and December 2014 were collected.The serum of the 2 groups was measured by 1H NMR spectroscopy.Multivariate statistical analyses were performed to identify the characteristic metabolites in the 2 groups,including principal component analysis (PCA),partial least squares discriminant analysis (PLS-DA) and orthogonal partial least squares discriminant analysis (OPLS-DA).Observation indicators included:(1) multivariate statistical analysis of serum metabonomic profile,results of PCA,PLS-DA and OPLS-DA,(2) screening of metabolites.Measurement data with normal distribution were presented as x ± s.The comparison between groups was evaluated with the t test.The count data were analyzed using the chi-square test.Results (1) The multivariate statistical analysis of serum metabonomic profile:results of PCA showed that expression rates of principal component 1 (PC1) and principal component 2 (PC2) to original data were 54.9％ and 23.5％,with both cumulative contribution rate of 78.4％.Results of PLS-DA showed that the separative trend between PC group and control group was appeared,and variance of X and Y matrixes and predictive value were 0.254,0.816 and 0.385.Results of OPLS-DA showed that the differences of samples between the 2 groups were further increased,and differential metabolites were screened according to the distinction of scores between the 2 groups,value of R2X,R2Y and Q2 was 0.254,0.816 and 0.433.(2) Screening of metabolites:35 serum metabolites were detected in the 2 groups.Compared with the control group,levels of 3-hydroxybuyarate,citrate,formate,glutamate,isoleucine,methionine and phenylalanine in the PC group were elevated (r =0.524,0.511,0.656,0.566,0.503,0.498,0.648,P ＜0.05),and levels of 3-methylhistidine,alanine,glutamine,LDL and VLDL in the PC group were decreased (r =-0.607,-0.508,-0.560,-0.568,-0.559,P ＜ 0.05).Conclusions Compared with healthy controls,several amino acids,citrate and lipoproteins demonstrate the metabolic differences in the serum of patients with pancreatic cancer.NMR based metabonomic profile technology can distinguish the difference of serum metabolites between patients with pancreatic cancer and healthy controls.NMR based metabonomic technology may be a promising method for the diagnosis of pancreatic cancer.

Proton Nuclear Magnetic Resonance Spectroscopy-Based Metabonomic Research on Pancreatic Cancer Tissue

Distinguishing Pancreatic Cancer from Chronic Pancreatitis and Healthy Individuals by 1H Nuclear Magnetic Resonance-Based Metabonomic Profiles

Analysis of Nuclear Magnetic Resonance-Based Metabonomics of Pancreatic Cancer

Metabolomic Profiling of Serum from Human Pancreatic Cancer Patients Using 1H NMR Spectroscopy and Principal Component Analysis

Metabonomic Changes from Pancreatic Intraepithelial Neoplasia to Pancreatic Ductal Adenocarcinoma in Tissues from Rats

¹H NMR-based metabolic profiling of human rectal cancer tissue

Metabolite detection of pancreatic carcinoma by in vivo proton MR spectroscopy at 3T: initial results

Metabonomic alterations from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma facilitate the identification of biomarkers in serum for early diagnosis of pancreatic cancer

Metabonomic Studies of Pancreatic Cancer Response to Radiotherapy in a Mouse Xenograft Model Using Magnetic Resonance Spectroscopy and Principal Components Analysis

1 H-NMR based metabonomic profiling of human esophageal cancer tissue

Tissue metabolic profiling reveals major metabolic alteration in colorectal cancer

Discrimination of Metabolic Profiles of Pancreatic Cancer from Chronic Pancreatitis by High‐resolution Magic Angle Spinning 1H Nuclear Magnetic Resonance and Principal Components Analysis

Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction

Metabolic Profiling of Human Colorectal Cancer Using High Resolution 1H Nuclear Magnetic Resonance Spectroscopy

Metabonomic Characteristics of Human Lung Cancer Using High Resolution 1H NMR Spectroscopy and Multivariate Data Analysis

Non-invasively Predicting Differentiation of Pancreatic Cancer Through Comparative Serum Metabonomic Profiling

Metabolic Alterations in Pancreatic Cancer Detected by In Vivo 1H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, and Survival Outcome

Tissue Metabonomic Phenotyping for Diagnosis and Prognosis of Human Colorectal Cancer

Metabolomic Analyses Redefine the Biological Classification of Pancreatic Cancer and Correlate with Clinical Outcomes

Understanding metabolomic characteristics of pancreatic ductal adenocarcinoma by HR-MAS NMR detection of pancreatic tissues

1 H-NMR-based Metabolomics of Tumor Tissue for the Metabolic Characterization of Rat Hepatocellular Carcinoma Formation and Metastasis